Potassium-competitive acid blockers: Clinical pearls and practical insights.

IF 5.2 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Cleveland Clinic Journal of Medicine Pub Date : 2026-06-01 DOI:10.3949/ccjm.93a.25070

Hisham Wehbe, Claire Beveridge

引用次数: 0

Abstract

Potassium-competitive acid blockers (P-CABs) are a new class of acid-suppressing drugs; to date, only one of them (vonoprazan) has been approved for use in the United States. The authors of this article review how P-CABs (and vonoprazan in particular) differ from proton pump inhibitors (PPIs), evidence supporting their effectiveness, indications for vonoprazan, and ongoing and future studies.

查看原文本刊更多论文

钾竞争性酸阻滞剂：临床珍珠和实用见解。

钾竞争酸阻滞剂（p - cab）是一类新型的抑酸药物；到目前为止，其中只有一种（vonoprazan）被批准在美国使用。本文的作者回顾了p - cab（尤其是vonoprazan）与质子泵抑制剂（PPIs）的区别，支持其有效性的证据，vonoprazan的适应症，以及正在进行和未来的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cleveland Clinic Journal of Medicine 医学-医学：内科

CiteScore

3.80

自引率

0.00%

发文量

109

审稿时长

6-12 weeks

期刊介绍： The mission of Cleveland Clinic Journal of Medicine (CCJM) is to provide its readers with up-to-date, practical, clinical information relevant to internal medicine, cardiology, and related fields. Consistent with this mission, CCJM focuses on timely review articles and other content that has a continuing-education orientation rather than on original research or case reports. CCJM authors, drawn from Cleveland Clinic and other top medical institutions throughout the world, are asked to identify new findings that are changing the practice of medicine and to advise readers how to apply them in daily patient care. Authors are chosen for their experience, acquired through caring for patients, teaching other physicians, and researching clinical questions.